The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections (UTIs), the first such drug approved in decades and the first in a new class of medications.

In the current case series, daptomycin was shown to be a safe and effective therapeutic option in the management of VRE UTIs. Because of the increasing prevalence of VRE infection and the limited ...

The U.S. Food and Drug Administration just approved the first new antibiotic to treat urinary tract infections in nearly ... Citrobacter freundii complex, Enterococcus faecalis, and a type of ...

GSK is opening the door to a new era in urinary tract infection (UTI ... Staphylococcus saprophyticus or Enterococcus faecalis in women 12 years of age and older. These types of UTIs are the ...

Opens in a new tab or window The FDA approved oral gepotidacin (Blujepa) for uncomplicated urinary tract infections (UTIs) in women and girls ages 12 years and up, GSK announced on Tuesday.

Background Vancomycin-resistant enterococci are a leading cause of hospital-acquired urinary tract infection and a growing concern for the clinician. The aim of this study was to evaluate the ...